All studies
Ongoing, recruitingTherapeutic confirmatory (Phase III)Interventional
J2T-MC-KGBI/DRM06-AD13: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age with Moderate-to-Severe Atopic Dermatitis
At a glance
Status
Ongoing, recruiting
Phase
Therapeutic confirmatory (Phase III)
Sponsor
Eli Lilly & Co.
Enrolment target
89
Start
04 Jul 2023
What is this study about?
Percentage of Participants with an Investigator Global Assessment (IGA) score 0 or 1 and a Reduction ≥2 points from Baseline, Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) ≥75% Reduction from Baseline in EASI Score
Who may be eligible?
Age any to any · Sex: All
Locations (5)
- —Poland
- —Spain
- —Czechia
- —Germany
- —France
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.